Agreed, a few diseases in particular have recently been revolutionised by use of mabs targeting specific cytokines (Crohn's, asthma etc.) however OA remains elusive. Toci (IL-6) has been tried for OA without much benefit. Whilst a different MOA I think colchicine will be used more and more going forward. There are some OA TNF-a trials going on. None seem to do the trick though!
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-202
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
-0.010(5.00%) |
Mkt cap ! $66.54M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.0¢ | $203.4K | 1.019M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 387930 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 65468 | 2 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |